Anthropic Confirms Own Wet Lab for Claude‑Driven Robot Experiments
On 18 September 2026, Eric Cauderer‑Abrams, head of Anthropic’s life sciences division, told Reuters that the company owns and operates its own “wet” laboratory in the San Francisco Bay area. The facility lets Claude direct robots to run experiments with minimal human involvement, though a human operator remains required for safety. A company spokesperson said the lab focuses on fundamental biology, not drug development.
Previously Anthropic was known mainly for providing tools to external labs; in April it bought startup Coefficient Bio for $400 million in stock. In June it launched Claude Science, a workbench for researchers, and announced preclinical programs for diseases that are not profitable for pharma. In August Claude designed 1320 mini‑proteins for 15 targets, and two external contract labs verified the binding while Anthropic itself did not touch the test tubes.
Also in August Anthropic opened the Model Hardware Standard, letting AI agents remotely read and adjust external instruments; in one
🔗 Read original →
On 18 September 2026, Eric Cauderer‑Abrams, head of Anthropic’s life sciences division, told Reuters that the company owns and operates its own “wet” laboratory in the San Francisco Bay area. The facility lets Claude direct robots to run experiments with minimal human involvement, though a human operator remains required for safety. A company spokesperson said the lab focuses on fundamental biology, not drug development.
Previously Anthropic was known mainly for providing tools to external labs; in April it bought startup Coefficient Bio for $400 million in stock. In June it launched Claude Science, a workbench for researchers, and announced preclinical programs for diseases that are not profitable for pharma. In August Claude designed 1320 mini‑proteins for 15 targets, and two external contract labs verified the binding while Anthropic itself did not touch the test tubes.
Also in August Anthropic opened the Model Hardware Standard, letting AI agents remotely read and adjust external instruments; in one
🔗 Read original →
Scientific American
Autonomous labs are running science experiments 24/7
Robots and AI are running experiments around the clock, from battery chemistry to cancer therapies. But can they be trusted to get it right?
First thing after installing a neural interface: say 'I love you'
What should you do after installing a neural interface? Control drones, operate robotic arms, browse the internet, or hack megacorporation servers?
Many imagine futuristic feats right away.
But the first step is simpler: tell your significant other 'I love you'.
Only after that should you move on to piloting drones, hacking servers, or any other high‑tech activity.
🔗 Source: @solid_state_humanity
What should you do after installing a neural interface? Control drones, operate robotic arms, browse the internet, or hack megacorporation servers?
Many imagine futuristic feats right away.
But the first step is simpler: tell your significant other 'I love you'.
Only after that should you move on to piloting drones, hacking servers, or any other high‑tech activity.
🔗 Source: @solid_state_humanity
Telegram
Solid State Humanity
Что нужно сделать после установки нейроинтерфейса? Управлять дронами, робо-руками, выходить в интернет, взламывать сервера мегакорпопаций?
Нет, конечно, сперва надо сказать своей второй половинке "я тебя люблю". А потом заниматься всем перечисленным
Нет, конечно, сперва надо сказать своей второй половинке "я тебя люблю". А потом заниматься всем перечисленным
Madrid Longevity March to Demand Recognition of Aging as Medical Target
On 1 October, International Day of Longevity, the International Longevity Alliance will stage a march from Spain’s Royal National Academy of Medicine to the City Hall palace of Cibeles in Madrid. The procession will pass Puerta del Sol and the Congress of Deputies, with four stops where participants will read the Madrid Longevity Declaration of 2023.
The march coincides with the International Longevity Summit, both events led by summit organizing committee chair José Cordeiro. According to Longevity.Technology, 18 September, the route symbolically links academic medicine, parliament, and municipal authority, turning a scientific argument into a political demand for recognizing aging as a medical target and securing its funding.
The 2023 declaration notes that germ cells, cancer cells, and certain hydra and jellyfish are biologically immortal, and it cites the 2012 Nobel Prize awarded to Japanese biologist Shinya Yamanaka for showing that mature cells can be reprogrammed to a stem‑cell state. It asserts that rejuvenating the organism is now merely a matter of time, quoting Aubrey de Grey’s 2011 line — “The first person who will live to 150 years has already been born” — and adding David Sinclair’s view that “Aging is a disease, the most common one, and it needs to be treated aggressively.”
José Cordeiro, an MIT engineer and prominent transhumanist, authored the 2018 bestseller *The Death of Death*, translated into eight languages, which argues that with sufficient funding death could become optional by 2045. He calls the march “the biggest public longevity march in history” but stresses that “This is only beginning,” explaining that the goal is not to celebrate aging as it exists today but to end the diseases that make aging feared.
Organizers point to Eurostat data showing life expectancy at birth in the Madrid community rose from 84.3–85.7 years (2014–2024), keeping Spain among Europe’s longest‑lived populations. International Day of Longevity was established in 2013 by activist Ilya Stambler and had previously been marked by local lectures and petitions in Italy, Brazil, and Pakistan. The growing size of the International Longevity Summit in Madrid — now hosted by the Royal Academy of Medicine — has finally given the movement critical mass, taking the conversation from conferences and labs onto the streets, as noted by Longevity.Technology.
🔗 Read original →
On 1 October, International Day of Longevity, the International Longevity Alliance will stage a march from Spain’s Royal National Academy of Medicine to the City Hall palace of Cibeles in Madrid. The procession will pass Puerta del Sol and the Congress of Deputies, with four stops where participants will read the Madrid Longevity Declaration of 2023.
The march coincides with the International Longevity Summit, both events led by summit organizing committee chair José Cordeiro. According to Longevity.Technology, 18 September, the route symbolically links academic medicine, parliament, and municipal authority, turning a scientific argument into a political demand for recognizing aging as a medical target and securing its funding.
The 2023 declaration notes that germ cells, cancer cells, and certain hydra and jellyfish are biologically immortal, and it cites the 2012 Nobel Prize awarded to Japanese biologist Shinya Yamanaka for showing that mature cells can be reprogrammed to a stem‑cell state. It asserts that rejuvenating the organism is now merely a matter of time, quoting Aubrey de Grey’s 2011 line — “The first person who will live to 150 years has already been born” — and adding David Sinclair’s view that “Aging is a disease, the most common one, and it needs to be treated aggressively.”
José Cordeiro, an MIT engineer and prominent transhumanist, authored the 2018 bestseller *The Death of Death*, translated into eight languages, which argues that with sufficient funding death could become optional by 2045. He calls the march “the biggest public longevity march in history” but stresses that “This is only beginning,” explaining that the goal is not to celebrate aging as it exists today but to end the diseases that make aging feared.
Organizers point to Eurostat data showing life expectancy at birth in the Madrid community rose from 84.3–85.7 years (2014–2024), keeping Spain among Europe’s longest‑lived populations. International Day of Longevity was established in 2013 by activist Ilya Stambler and had previously been marked by local lectures and petitions in Italy, Brazil, and Pakistan. The growing size of the International Longevity Summit in Madrid — now hosted by the Royal Academy of Medicine — has finally given the movement critical mass, taking the conversation from conferences and labs onto the streets, as noted by Longevity.Technology.
🔗 Read original →
Nature
Is ageing a disease? The debate that could reshape medicine
Nature - Classifying ageing as a disease might bring funding and other benefits, say some researchers, but others say this is fraught with ethical and regulatory implications.
Two‑Decade Review Links Nuclear Defect to Progeria’s Multi‑Level Damage
Professor Karim Jabali of the Technical University of Munich published a twenty‑year review of Hutchinson‑Gilford progeria on 17 September in Mechanisms of Ageing and Development. The paper synthesises research from 2002 onward into a single causal chain that connects a nuclear defect to cellular, tissue, and organismal decline.
The disease stems from a single LMNA mutation that prevents removal of a farnesyl tail from progerin, a truncated lamin A protein. Because the tail remains attached, progerin sticks irreversibly to the inner nuclear membrane, distorting the nucleus. Cells appear deformed under microscopy but divide and function normally until a heat shock reveals their inability to recover, unlike healthy cells.
Nuclear pores assemble correctly after division but gradually clump with age, and progerin accumulates over time, especially in vascular cells where it persists for weeks. This selective buildup explains why the heart and arteries suffer most despite ubiquitous LMNA expression. Similar low‑level progerin appears in ageing skin and in kidney‑disease‑damaged vessels, linking the defect to normal ageing processes.
At the cellular level, nuclear damage overwhelms the protein‑clearance system, and weakened clearance accelerates further progerin buildup—a vicious cycle. Sulforaphane from broccoli and rapamycin can restore this clearance and ease cellular symptoms, though they do not eliminate them.
Tissue‑level damage creates a second cycle: senescent cells release inflammatory signals that drive neighbouring cells to age faster. The approved drug baricitinib dampens this signal; combined with lonafarnib it extends mouse lifespan more than either agent alone. Lonafarnib, the only progeria therapy with proven survival benefit, was approved in the United States in 2020 and acts at the nuclear level by weakening progerin’s membrane attachment.
Jabali proposes adding baricitinib and sulforaphane to target tissue and cellular levels while awaiting more radical tools. Genome editing that corrects the LMNA mutation—or an approach that bypasses the mutation—has raised mouse lifespan 2.4‑fold, but such treatments are not yet available to children. Key nuclear and cellular experiments come from her lab (active since 2002); tissue and organismal data derive from independent studies. Jabali earned her doctorate under Nobel laureate Günter Blobel, who discovered cellular protein‑targeting signals, and her work on nuclear‑pore clumping extends that legacy. She concludes: “HGPS is not a copy of physiological ageing but a genetically programmed system that shows how persistent nuclear stress progressively erodes the organism’s conservative adaptive networks.”
🔗 Read original →
Professor Karim Jabali of the Technical University of Munich published a twenty‑year review of Hutchinson‑Gilford progeria on 17 September in Mechanisms of Ageing and Development. The paper synthesises research from 2002 onward into a single causal chain that connects a nuclear defect to cellular, tissue, and organismal decline.
The disease stems from a single LMNA mutation that prevents removal of a farnesyl tail from progerin, a truncated lamin A protein. Because the tail remains attached, progerin sticks irreversibly to the inner nuclear membrane, distorting the nucleus. Cells appear deformed under microscopy but divide and function normally until a heat shock reveals their inability to recover, unlike healthy cells.
Nuclear pores assemble correctly after division but gradually clump with age, and progerin accumulates over time, especially in vascular cells where it persists for weeks. This selective buildup explains why the heart and arteries suffer most despite ubiquitous LMNA expression. Similar low‑level progerin appears in ageing skin and in kidney‑disease‑damaged vessels, linking the defect to normal ageing processes.
At the cellular level, nuclear damage overwhelms the protein‑clearance system, and weakened clearance accelerates further progerin buildup—a vicious cycle. Sulforaphane from broccoli and rapamycin can restore this clearance and ease cellular symptoms, though they do not eliminate them.
Tissue‑level damage creates a second cycle: senescent cells release inflammatory signals that drive neighbouring cells to age faster. The approved drug baricitinib dampens this signal; combined with lonafarnib it extends mouse lifespan more than either agent alone. Lonafarnib, the only progeria therapy with proven survival benefit, was approved in the United States in 2020 and acts at the nuclear level by weakening progerin’s membrane attachment.
Jabali proposes adding baricitinib and sulforaphane to target tissue and cellular levels while awaiting more radical tools. Genome editing that corrects the LMNA mutation—or an approach that bypasses the mutation—has raised mouse lifespan 2.4‑fold, but such treatments are not yet available to children. Key nuclear and cellular experiments come from her lab (active since 2002); tissue and organismal data derive from independent studies. Jabali earned her doctorate under Nobel laureate Günter Blobel, who discovered cellular protein‑targeting signals, and her work on nuclear‑pore clumping extends that legacy. She concludes: “HGPS is not a copy of physiological ageing but a genetically programmed system that shows how persistent nuclear stress progressively erodes the organism’s conservative adaptive networks.”
🔗 Read original →
Nature
Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome
Nature - Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome
Senolytic drugs restore motor cortex function in ALS mouse model
On September 18, Neurobiology of Disease, September 18 published a study from the University of Missouri showing that signs of cellular senescence appear early in the brains of mice carrying the TDP-43 Q331K mutation, before full ALS disease onset. The researchers used this mouse model to test whether removing senescent cells could alter disease progression.
Fifteen weeks of treatment with the senolytic combination dasatinib and quercetin (D&Q) — first tried in humans in 2019 for pulmonary fibrosis — was administered to a cohort of the mice. In earlier pilot studies in elderly people at
🔗 Read original →
On September 18, Neurobiology of Disease, September 18 published a study from the University of Missouri showing that signs of cellular senescence appear early in the brains of mice carrying the TDP-43 Q331K mutation, before full ALS disease onset. The researchers used this mouse model to test whether removing senescent cells could alter disease progression.
Fifteen weeks of treatment with the senolytic combination dasatinib and quercetin (D&Q) — first tried in humans in 2019 for pulmonary fibrosis — was administered to a cohort of the mice. In earlier pilot studies in elderly people at
🔗 Read original →
PubMed Central (PMC)
Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies
Amyotrophic Lateral Sclerosis (ALS) is a group of sporadic and genetic neurodegenerative disorders that result in losses of upper and lower motor neurons. Treatment of ALS is limited, and survival is 2–5 years after disease onset. While ALS can ...
HA-Tau nanospheres capture inflammatory proteins and restore memory in aged mice
The team from Duke University and UCLA described HA‑Tau — hyaluronic acid conjugated with taurine and formed into nanospheres of about ~200 nanometers — in a preprint dated September 18, 2026 preprint, September 18, 2026. One injection of these nanospheres into old mice after a bone fracture lowered inflammatory proteins in the blood, preserved the blood‑brain barrier, and returned spatial‑memory performance to normal levels.
In 20–22‑month‑old mice (equivalent to elderly humans) the nanospheres administered 30 minutes after a tibial fracture captured roughly ~548 different proteins from plasma, most of them belonging to inflammatory pathways. Levels of IL‑6, IL‑1β and TNF‑α dropped, barrier‑strengthening proteins remained, dye leakage decreased, and glial activation in the hippocampus — the memory centre — nearly returned to baseline, so memory test scores matched those of non‑operated animals.
Molecular docking showed that a partial substitution of taurine for hyaluronic acid — around ~43% — creates new cytokine‑binding sites while strengthening existing ones; full substitution abolishes both effects due to steric hindrance. This optimal degree was chosen by direct testing on blood proteins, where it bound best. Taurine’s controversial reputation in geroscience — highlighted by a Science 2023 article linking low taurine to aging and lifespan extension in mice, though later human data failed to confirm the link — is repurposed here simply as a hook for cytokines.
Tests on plasma from elderly donors and human brain‑vascular cells reproduced the same effect: the nanospheres captured IL‑6, IL‑1β and TNF‑α, which signal through the NF‑κB switch, and made the barrier less permeable than without them. This cytokine node has previously been tied to cognitive impairment in living people by Canadian data.
The nanospheres barely enter the brain and accumulate mainly in the liver, causing no detectable liver damage within the first day; the brain is protected because the substance that intercepts the inflammatory signals never needs to cross the blood‑brain barrier.
🔗 Read original →
The team from Duke University and UCLA described HA‑Tau — hyaluronic acid conjugated with taurine and formed into nanospheres of about ~200 nanometers — in a preprint dated September 18, 2026 preprint, September 18, 2026. One injection of these nanospheres into old mice after a bone fracture lowered inflammatory proteins in the blood, preserved the blood‑brain barrier, and returned spatial‑memory performance to normal levels.
In 20–22‑month‑old mice (equivalent to elderly humans) the nanospheres administered 30 minutes after a tibial fracture captured roughly ~548 different proteins from plasma, most of them belonging to inflammatory pathways. Levels of IL‑6, IL‑1β and TNF‑α dropped, barrier‑strengthening proteins remained, dye leakage decreased, and glial activation in the hippocampus — the memory centre — nearly returned to baseline, so memory test scores matched those of non‑operated animals.
Molecular docking showed that a partial substitution of taurine for hyaluronic acid — around ~43% — creates new cytokine‑binding sites while strengthening existing ones; full substitution abolishes both effects due to steric hindrance. This optimal degree was chosen by direct testing on blood proteins, where it bound best. Taurine’s controversial reputation in geroscience — highlighted by a Science 2023 article linking low taurine to aging and lifespan extension in mice, though later human data failed to confirm the link — is repurposed here simply as a hook for cytokines.
Tests on plasma from elderly donors and human brain‑vascular cells reproduced the same effect: the nanospheres captured IL‑6, IL‑1β and TNF‑α, which signal through the NF‑κB switch, and made the barrier less permeable than without them. This cytokine node has previously been tied to cognitive impairment in living people by Canadian data.
The nanospheres barely enter the brain and accumulate mainly in the liver, causing no detectable liver damage within the first day; the brain is protected because the substance that intercepts the inflammatory signals never needs to cross the blood‑brain barrier.
🔗 Read original →
Glycocalyx‑edited stem cells reverse osteoporosis in small trial
The approach uses a patient’s own mesenchymal stromal/stem cells (MSCs) harvested from bone marrow, which are bioengineered to restore surface expression of the molecule sLeX. This glyocalyx modification re‑equips the cells with the ability to home to bone marrow after intravenous infusion, turning them into a “living drug”
🔗 Read original →
The approach uses a patient’s own mesenchymal stromal/stem cells (MSCs) harvested from bone marrow, which are bioengineered to restore surface expression of the molecule sLeX. This glyocalyx modification re‑equips the cells with the ability to home to bone marrow after intravenous infusion, turning them into a “living drug”
🔗 Read original →
Cell
Glycocalyx-edited mesenchymal stem/stromal cell therapy in advanced osteoporosis
Mesenchymal stem/stromal cell (MSC)-based therapy holds promise for reversal of bone
loss in osteoporosis. This phase 1 study establishes the safety and feasibility of
intravenous administration of glycocalyx-engineered human MSCs and provides evidence
that…
loss in osteoporosis. This phase 1 study establishes the safety and feasibility of
intravenous administration of glycocalyx-engineered human MSCs and provides evidence
that…
Naive CD8+ T cells pre‑mark mitochondrial genes with H2A.Z via GABPα and IL‑7 for rapid response
Naive CD8+ T cells mark mitochondrial genes with the histone variant H2A.Z under the direction of GABPα and the background signal IL‑7, allowing them to launch a full effector response within hours of encountering their specific pathogen. This preparatory state weakens with age but can be restored, and the same mechanism enhances anticancer CAR‑T therapy.
The study was conducted by a group from the Chinese Academy of Sciences and published in Science Advances, 18 September. A year earlier the same lab showed that H2A.Z primes memory CD8+ T cells for rapid action; the new work extends this finding to naïve cells that have not yet met a pathogen.
A naive CD8+ T cell is a killer lymphocyte that conserves resources while waiting for its target. Upon recognizing the appropriate threat it has only a few hours to proliferate, produce effector proteins, and remodel its metabolism. How this readiness is kept on pause for years had remained unclear; the answer lies in DNA packaging.
H2A.Z is a histone “spool” around which DNA is wound to fit two meters of genome into a microscopic nucleus. Where H2A.Z resides, chromatin is looser and genes are easier to activate. Mice lacking H2A.Z in T cells show diminished naïve and effector populations, and the remaining cells poorly control a model bacterial infection and melanoma tumor growth.
The defect is specific: without H2A.Z, mitochondrial respiratory‑chain genes activate far less strongly upon stimulation, and adding pure ATP to the culture partially restores activation capacity—indicating that an energy shortage keeps the cells idle.
Mass‑spectrometry identified the depositor of H2A.Z on these genes as GABPα, known since the 1990s as
🔗 Read original →
Naive CD8+ T cells mark mitochondrial genes with the histone variant H2A.Z under the direction of GABPα and the background signal IL‑7, allowing them to launch a full effector response within hours of encountering their specific pathogen. This preparatory state weakens with age but can be restored, and the same mechanism enhances anticancer CAR‑T therapy.
The study was conducted by a group from the Chinese Academy of Sciences and published in Science Advances, 18 September. A year earlier the same lab showed that H2A.Z primes memory CD8+ T cells for rapid action; the new work extends this finding to naïve cells that have not yet met a pathogen.
A naive CD8+ T cell is a killer lymphocyte that conserves resources while waiting for its target. Upon recognizing the appropriate threat it has only a few hours to proliferate, produce effector proteins, and remodel its metabolism. How this readiness is kept on pause for years had remained unclear; the answer lies in DNA packaging.
H2A.Z is a histone “spool” around which DNA is wound to fit two meters of genome into a microscopic nucleus. Where H2A.Z resides, chromatin is looser and genes are easier to activate. Mice lacking H2A.Z in T cells show diminished naïve and effector populations, and the remaining cells poorly control a model bacterial infection and melanoma tumor growth.
The defect is specific: without H2A.Z, mitochondrial respiratory‑chain genes activate far less strongly upon stimulation, and adding pure ATP to the culture partially restores activation capacity—indicating that an energy shortage keeps the cells idle.
Mass‑spectrometry identified the depositor of H2A.Z on these genes as GABPα, known since the 1990s as
🔗 Read original →
PubMed Central (PMC)
Epigenetic training licenses naïve CD8+ T cell metabolic fitness and function
Naïve T cells maintain quiescence yet must respond rapidly to antigens, but how they prime this capacity is unclear. We identify histone variant H2A.Z as a key regulator of an epigenetic training program that licenses quiescent naïve CD8+ T cells ...
China adds xenotransplantation, universal cell therapy, and organ growing to 2030 medical industry plan
On September 18 ten Chinese agencies led by the Ministry of Industry and Information Technology released document No. 210 – the medical industry development plan for 2026‑2030. Among its ten targets are industry revenue of 3.5 trillion yuan (~$523 billion) and at least a quarter of global first‑in‑class drugs originating from China.
The plan calls for technological breakthroughs in xenotransplantation (animal‑to‑human organ transplants), universal cell therapy with off‑the‑shelf products, creation of complex regenerable organs, and synthesis of artificial living systems (building functional biological systems from scratch). It also urges expansion of next‑generation genome editing and neuro‑interfaces that link the brain to computers.
Continuing the previous industrial cycle, China launched 230 innovative drugs during 2021‑2025 and ranked second worldwide in drugs under development, per the ministry’s explanation. The plan links this effort to accelerating population aging: by end‑2025 323.38 million people aged 60+ (23 % of the population), according to the National Bureau of Statistics National Bureau of Statistics.
In the traditional Chinese medicine section, anti‑aging agents are listed among new consumer directions alongside elderly care, rehabilitation, and health management. For rare diseases it speeds development of cell and gene therapies – e.g., hemophilia, ALS, and Gaucher disease.
In the first half of 2026 licensing deals for Chinese innovative drugs reached $106.3 billion, versus $135.7 billion for all of 2025. The plan connects these industry scales to concrete technology targets through 2030.
🔗 Read original →
On September 18 ten Chinese agencies led by the Ministry of Industry and Information Technology released document No. 210 – the medical industry development plan for 2026‑2030. Among its ten targets are industry revenue of 3.5 trillion yuan (~$523 billion) and at least a quarter of global first‑in‑class drugs originating from China.
The plan calls for technological breakthroughs in xenotransplantation (animal‑to‑human organ transplants), universal cell therapy with off‑the‑shelf products, creation of complex regenerable organs, and synthesis of artificial living systems (building functional biological systems from scratch). It also urges expansion of next‑generation genome editing and neuro‑interfaces that link the brain to computers.
Continuing the previous industrial cycle, China launched 230 innovative drugs during 2021‑2025 and ranked second worldwide in drugs under development, per the ministry’s explanation. The plan links this effort to accelerating population aging: by end‑2025 323.38 million people aged 60+ (23 % of the population), according to the National Bureau of Statistics National Bureau of Statistics.
In the traditional Chinese medicine section, anti‑aging agents are listed among new consumer directions alongside elderly care, rehabilitation, and health management. For rare diseases it speeds development of cell and gene therapies – e.g., hemophilia, ALS, and Gaucher disease.
In the first half of 2026 licensing deals for Chinese innovative drugs reached $106.3 billion, versus $135.7 billion for all of 2025. The plan connects these industry scales to concrete technology targets through 2030.
🔗 Read original →
www.miit.gov.cn
工业和信息化部等十部门关于印发《医药工业发展“十五五”规划》的通知
工信部联规﹝2026﹞210号各省、自治区、直辖市、计划单列市及新疆生产建设兵团工业和信息化、发展改革、自然资源、农业农村、商务、卫生健康、应急、医保、中医药、药监主管部门：现将《医药工业发展“十五五”规划》印发给你们，请结合实际，认真贯彻实施。工业和信息化部国家发展改革委自然资源部农业农村部商务部国家卫生健康委应急管理部国家医保局国家中医药局国家药监局2026年8月28日
FDA Accepts Reasonable Expectation of Effectiveness Package for Loyal’s LOY-003
On September 16, the FDA accepted an interim submission for Loyal’s LOY-003 that includes a “reasonable expectation of effectiveness” (RXE) determination. This marks the third RXE granted to separate Loyal programs, according to the company. The RXE step evaluates whether a future drug can deliver the claimed benefit.
LOY-003 is a daily tablet designed for large and giant breeds that aims to extend their lifespan. Loyal links the shorter life of these dogs to the hormonal signals GH and IGF-1, which influence body growth. The tablet is intended
🔗 Read original →
On September 16, the FDA accepted an interim submission for Loyal’s LOY-003 that includes a “reasonable expectation of effectiveness” (RXE) determination. This marks the third RXE granted to separate Loyal programs, according to the company. The RXE step evaluates whether a future drug can deliver the claimed benefit.
LOY-003 is a daily tablet designed for large and giant breeds that aims to extend their lifespan. Loyal links the shorter life of these dogs to the hormonal signals GH and IGF-1, which influence body growth. The tablet is intended
🔗 Read original →
PubMed Central (PMC)
Connecting serum IGF-1, body size, and age in the domestic dog
Many investigations in recent years have targeted understanding the genetic and biochemical basis of aging. Collectively, genetic factors and biological mechanisms appear to influence longevity in general and specifically; reduction of the ...
Calorie restriction primes mice for fasting hours before the stomach empties
Researchers from Roman Kondratov’s lab at Cleveland State University compared calorie restriction (CR) with a single fast‑feed‑fast cycle (FRF) that delivered the same total amount of food and the same total fasting time. Mice on CR received 70% of their normal ration in one daily meal, ate it within two hours, and then fasted for about 22 hours. The FRF group underwent one 22‑hour fast, a two‑hour feed, then another 22‑hour fast.
In the CR mice, metabolic switches to a fasting mode began many hours before the stomach was empty—insulin fell already after two hours and mTOR activity dropped after six hours, roughly 12 hours before the stomach became empty at around the 18‑hour mark. In the FRF mice, insulin and mTOR changes tracked stomach emptying closely, occurring only after the stomach was nearly empty at about six hours.
The study showed that only CR improved glucose tolerance and kept liver fat low, whereas the FRF mice displayed sharp post‑meal glucose spikes, no improvement in glucose tolerance, and a progressive accumulation of liver fat that peaked around the 18‑hour fasting point.
These results were published 17 September in Cell Reports. The work also builds on earlier findings that functional circadian clocks are required for CR‑mediated lifespan extension, and that the circadian protein PER2 can bind mTOR to tune its response to fasting—a mechanism highlighted in a separate September study.
The 2017 Nobel Prize in Physiology or Medicine was awarded to Jeffrey Hall, Michael Rosbash and Michael Young for elucidating the molecular mechanism of circadian clocks.
🔗 Read original →
Researchers from Roman Kondratov’s lab at Cleveland State University compared calorie restriction (CR) with a single fast‑feed‑fast cycle (FRF) that delivered the same total amount of food and the same total fasting time. Mice on CR received 70% of their normal ration in one daily meal, ate it within two hours, and then fasted for about 22 hours. The FRF group underwent one 22‑hour fast, a two‑hour feed, then another 22‑hour fast.
In the CR mice, metabolic switches to a fasting mode began many hours before the stomach was empty—insulin fell already after two hours and mTOR activity dropped after six hours, roughly 12 hours before the stomach became empty at around the 18‑hour mark. In the FRF mice, insulin and mTOR changes tracked stomach emptying closely, occurring only after the stomach was nearly empty at about six hours.
The study showed that only CR improved glucose tolerance and kept liver fat low, whereas the FRF mice displayed sharp post‑meal glucose spikes, no improvement in glucose tolerance, and a progressive accumulation of liver fat that peaked around the 18‑hour fasting point.
These results were published 17 September in Cell Reports. The work also builds on earlier findings that functional circadian clocks are required for CR‑mediated lifespan extension, and that the circadian protein PER2 can bind mTOR to tune its response to fasting—a mechanism highlighted in a separate September study.
The 2017 Nobel Prize in Physiology or Medicine was awarded to Jeffrey Hall, Michael Rosbash and Michael Young for elucidating the molecular mechanism of circadian clocks.
🔗 Read original →
TH1834 protects human heart cells from reperfusion injury after heart attack
TH1834 blocking TIP60 protected human heart cells and mini‑tissues grown from stem cells from damage during reperfusion after a heart attack — an effect previously demonstrated only in mice.
Rest
🔗 Read original →
TH1834 blocking TIP60 protected human heart cells and mini‑tissues grown from stem cells from damage during reperfusion after a heart attack — an effect previously demonstrated only in mice.
Rest
🔗 Read original →
Claude autonomously GPU‑optimizes 36 open‑source biomolecule tools, boosting speed up to 4.1×
On September 17 Anthropic released the Anthropic technical report showing that its research model Claude autonomously optimized code for 36 versions of more than 30 open‑source scientific programs that predict protein 3D shape, design molecules, and analyze genomic data. Two staff members with biology knowledge but no GPU‑coding experience led the effort. Speed and accuracy were validated on thousands of predictions, and all code was made open.
The programs spend most of their compute on triple‑segment comparisons; doubling a molecule’s size raises the cost eight‑fold. Acceleration comes from rewriting low‑level GPU kernels. Claude wrote a set of FlashPairformer kernels that
🔗 Read original →
On September 17 Anthropic released the Anthropic technical report showing that its research model Claude autonomously optimized code for 36 versions of more than 30 open‑source scientific programs that predict protein 3D shape, design molecules, and analyze genomic data. Two staff members with biology knowledge but no GPU‑coding experience led the effort. Speed and accuracy were validated on thousands of predictions, and all code was made open.
The programs spend most of their compute on triple‑segment comparisons; doubling a molecule’s size raises the cost eight‑fold. Acceleration comes from rewriting low‑level GPU kernels. Claude wrote a set of FlashPairformer kernels that
🔗 Read original →
bioRxiv
Boltz-2: Towards Accurate and Efficient Binding Affinity Prediction
Accurately modeling biomolecular interactions is a central challenge in modern biology. While recent advances, such as AlphaFold3 and Boltz-1, have substantially improved our ability to predict biomolecular complex structures, these models still fall short…
Platelet protein PF4 links exercise, Klotho, young plasma to rejuvenation and clot risk
A review in Frontiers in Immunology, September 2 synthesizes three 2023 studies showing that exercise, the longevity factor Klotho, and young plasma all raise levels of the platelet protein PF4 in old mice. PF4 then reduces brain inflammation, boosts newborn neurons, and repairs immune cells and bone marrow.
🔗 Read original →
A review in Frontiers in Immunology, September 2 synthesizes three 2023 studies showing that exercise, the longevity factor Klotho, and young plasma all raise levels of the platelet protein PF4 in old mice. PF4 then reduces brain inflammation, boosts newborn neurons, and repairs immune cells and bone marrow.
🔗 Read original →
Scientific American
FDA Issues Warning about Young-Blood Transfusions
Plasma from young people offers “no proven clinical benefit” as a treatment against aging or Alzheimer’s disease, the agency says
DNA methylation blood study shows most CpG links stable with age, some reconfigured
On 18 September researchers posted a preprint on DNA methylation in whole blood from more than 7500 individuals aged 17 to 99. They focused on CpG sites and defined modules as groups of sites that usually change together.
After removing the average age‑related methylation shift, they built a module network from the youngest group (<36 years) and compared it to seven older groups, isolating changes in connections between sites rather than overall shifts.
The network contained 69 modules; they kept the 53 largest for further analysis. About 70% of these modules showed no significant change in connectivity with age, while 11 modules lost more than 5% of their connectivity from the youngest to the oldest group.
Stable modules tended to lie near gene promoters and in long‑range DNA contacts, whereas changing modules were found in late‑replicating, tightly packed chromatin. The approach builds on work from 2023 that compared similar methylation modules across 348 mammalian species and linked them to biological traits.
🔗 Read original →
On 18 September researchers posted a preprint on DNA methylation in whole blood from more than 7500 individuals aged 17 to 99. They focused on CpG sites and defined modules as groups of sites that usually change together.
After removing the average age‑related methylation shift, they built a module network from the youngest group (<36 years) and compared it to seven older groups, isolating changes in connections between sites rather than overall shifts.
The network contained 69 modules; they kept the 53 largest for further analysis. About 70% of these modules showed no significant change in connectivity with age, while 11 modules lost more than 5% of their connectivity from the youngest to the oldest group.
Stable modules tended to lie near gene promoters and in long‑range DNA contacts, whereas changing modules were found in late‑replicating, tightly packed chromatin. The approach builds on work from 2023 that compared similar methylation modules across 348 mammalian species and linked them to biological traits.
🔗 Read original →
CFTR modulator reverses biological aging in cystic fibrosis patients
Eight previously untreated cystic fibrosis patients received elexacaftor/tezacaftor/ivacaftor (ETI) for one year; their median epigenetic age acceleration shifted from +1.92 years to -1.70 years (p=0.008). The findings were reported in a preprint posted September 18, 2024 by researchers at the University of British Columbia.
ETI, marketed as Trikafta/Kaftrio, was approved in 2019 and is suitable for roughly 90% of CF patients; it markedly improves sweat chloride and lung function. In this cohort sweat chloride dropped from 98 to 41 mmol/L and lung function rose from 64.5% to 90% of normal.
Higher epigenetic age acceleration correlated with elevated blood IL‑6, IL‑1β and calprotectin, while DNAmGrimAge2—a clock trained to predict mortality and chronic disease—reflects lung aging. Improved lung function was linked to slower epigenetic aging, whereas higher sweat chloride pointed to faster aging.
An earlier Italian study of 52 adults showed a similar reduction in epigenetic age with ETI; this preprint replicates the observation using a different clock and directly ties the effect to inflammation markers. The synchronized changes in sweat chloride, lung function, inflammation and epigenetic age in the same eight individuals support the hypothesis that epigenetic aging in CF can reverse as rapidly as biochemical markers when CFTR function is restored.
🔗 Read original →
Eight previously untreated cystic fibrosis patients received elexacaftor/tezacaftor/ivacaftor (ETI) for one year; their median epigenetic age acceleration shifted from +1.92 years to -1.70 years (p=0.008). The findings were reported in a preprint posted September 18, 2024 by researchers at the University of British Columbia.
ETI, marketed as Trikafta/Kaftrio, was approved in 2019 and is suitable for roughly 90% of CF patients; it markedly improves sweat chloride and lung function. In this cohort sweat chloride dropped from 98 to 41 mmol/L and lung function rose from 64.5% to 90% of normal.
Higher epigenetic age acceleration correlated with elevated blood IL‑6, IL‑1β and calprotectin, while DNAmGrimAge2—a clock trained to predict mortality and chronic disease—reflects lung aging. Improved lung function was linked to slower epigenetic aging, whereas higher sweat chloride pointed to faster aging.
An earlier Italian study of 52 adults showed a similar reduction in epigenetic age with ETI; this preprint replicates the observation using a different clock and directly ties the effect to inflammation markers. The synchronized changes in sweat chloride, lung function, inflammation and epigenetic age in the same eight individuals support the hypothesis that epigenetic aging in CF can reverse as rapidly as biochemical markers when CFTR function is restored.
🔗 Read original →
PubMed Central (PMC)
Pulmonary Function Modulates Epigenetic Age in Subjects with Cystic Fibrosis
Cystic fibrosis (CF) is the most common severe autosomal recessive disease among Caucasians. Modulators of cystic fibrosis transmembrane conductance regulator (CFTR) mutated protein significantly improved the outcome of subjects with CF. In the ...
Mathematical control theory reframes aging as loss of safe manageability
The article by Alex Zhavoronkov, founder and CEO of Insilico Medicine, and mathematician Bad Mishra of the Courant Institute at New York University was published in Aging, September 16, 2026.
In their model the body is a point in the space of possible biological states, while drugs and other interventions are forces that push this point in different directions. Biological age is defined as the minimal cost in dose, risk, and time required to return the body to the zone of normal function.
Existing aging theories — López‑Otín’s hallmarks, Aubrey de Grey’s SENS, geroscience, and Blagosklonny’s hyper‑functional theory — describe what changes in cells and tissues with age, but they do not answer the practical question of which intervention, at what dose, and in what sequence to apply to a given organism now.
Six months earlier Zhavoronkov announced that aging clocks are dying and
🔗 Read original →
The article by Alex Zhavoronkov, founder and CEO of Insilico Medicine, and mathematician Bad Mishra of the Courant Institute at New York University was published in Aging, September 16, 2026.
In their model the body is a point in the space of possible biological states, while drugs and other interventions are forces that push this point in different directions. Biological age is defined as the minimal cost in dose, risk, and time required to return the body to the zone of normal function.
Existing aging theories — López‑Otín’s hallmarks, Aubrey de Grey’s SENS, geroscience, and Blagosklonny’s hyper‑functional theory — describe what changes in cells and tissues with age, but they do not answer the practical question of which intervention, at what dose, and in what sequence to apply to a given organism now.
Six months earlier Zhavoronkov announced that aging clocks are dying and
🔗 Read original →
Nature
Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts human lifespan limit
Nature Communications - Aging is associated with an increased risk of chronic diseases and functional decline. Here, the authors investigate the fluctuations of physiological indices along aging...
UK Study Links Neighborhood Deprivation, Crime, and Pollution to Faster Biological Aging
A large British study posted as a preprint on medRxiv on 16 September examined how 30 aspects of the residential environment relate to biological aging in 3307 adults from the UK Understanding Society cohort. The work was led by Gergö Baranyi of University College London and Cathryn Tonne of the Barcelona Institute for Global Health. They used methylation‑based DNA clocks to measure biological age, focusing on white participants only.
Five age‑estimation tests and four analytical methods converged on the same finding: the newest clocks that measure the pace of aging — especially DunedinPACE — showed the strongest links to environmental stressors. Older clocks such as Horvath and Hannum responded weakly, while PhenoAge showed intermediate sensitivity. Notably, the
🔗 Read original →
A large British study posted as a preprint on medRxiv on 16 September examined how 30 aspects of the residential environment relate to biological aging in 3307 adults from the UK Understanding Society cohort. The work was led by Gergö Baranyi of University College London and Cathryn Tonne of the Barcelona Institute for Global Health. They used methylation‑based DNA clocks to measure biological age, focusing on white participants only.
Five age‑estimation tests and four analytical methods converged on the same finding: the newest clocks that measure the pace of aging — especially DunedinPACE — showed the strongest links to environmental stressors. Older clocks such as Horvath and Hannum responded weakly, while PhenoAge showed intermediate sensitivity. Notably, the
🔗 Read original →
medRxiv
Multidomain residential external exposome and epigenetic ageing in the UK general population
Residential environmental exposures might be associated with biological ageing, but evidence has largely focused on a limited set of single exposures. We investigated associations between the multidomain residential external exposome and epigenetic ageing…
LDDM generative model designs binders for five proteins, with X‑ray confirmation of one predicted pose
A preprint from the EPFL team describing LDDM — a generative model that creates drug‑like molecules fitted to a target protein structure — was released on bioRxiv, September 18. The authors synthesized and tested the model’s proposals for five different proteins, confirming binding in all five cases; for one target the X‑ray pose matched the prediction almost exactly.
LDDM was trained on 836 thousand examples of hidden molecular fragments, a dataset 16 times larger than the entire collection of deciphered protein‑ligand structures in the main global database. By limiting each growth step to chemically purchasable blocks, the model builds synthesizable molecules directly during generation.
In the molecular‑glue experiment linking CDO1 to VHL for degradation, 67% of the LDDM‑designed variants retained nanomolar binding affinity. For a peptide inhibitor of cathepsin S — a cancer‑related enzyme on which the model had never been trained — a single‑amino‑acid substitution improved binding 3.5‑fold, from 70.4 nM to 19.9 nM.
For the metabolic enzyme PGK1 (linked to cancer, Parkinson’s and ALS), the best LDDM molecule bound at 14.7 µM, stronger than the control compound at 30 µM as verified by NMR. LDDM also produced a BRD4 binder with an affinity of 40–60 µM, whose NMR‑observed binding matched the model’s prediction. In the SARS‑CoV‑2 Mac1 challenge, LDDM screened only 57 molecules and identified a chemically distinct hit at 46.2 µM; X‑ray analysis confirmed its pose with an accuracy of 1.4–2.3 Å, whereas a public competition of 23 teams had yielded a best result near 18 µM after testing 1739 compounds.
The model failed to give a clear signal for KRAS, and for Pin1 the crystal pose differed from the prediction. Most hits remain below the potency needed for a drug candidate, which the authors view as a pragmatic compromise enabling experimental testing of designed molecules. Lead author Ilya Igashov — an MIPT graduate and EPFL PhD student under Bruno Correia and Oxford professor Michael Bronstein — notes that LDDM continues the lab’s four‑year trajectory from fragment‑based assembly to de‑novo design and synthesizability prediction.
🔗 Read original →
A preprint from the EPFL team describing LDDM — a generative model that creates drug‑like molecules fitted to a target protein structure — was released on bioRxiv, September 18. The authors synthesized and tested the model’s proposals for five different proteins, confirming binding in all five cases; for one target the X‑ray pose matched the prediction almost exactly.
LDDM was trained on 836 thousand examples of hidden molecular fragments, a dataset 16 times larger than the entire collection of deciphered protein‑ligand structures in the main global database. By limiting each growth step to chemically purchasable blocks, the model builds synthesizable molecules directly during generation.
In the molecular‑glue experiment linking CDO1 to VHL for degradation, 67% of the LDDM‑designed variants retained nanomolar binding affinity. For a peptide inhibitor of cathepsin S — a cancer‑related enzyme on which the model had never been trained — a single‑amino‑acid substitution improved binding 3.5‑fold, from 70.4 nM to 19.9 nM.
For the metabolic enzyme PGK1 (linked to cancer, Parkinson’s and ALS), the best LDDM molecule bound at 14.7 µM, stronger than the control compound at 30 µM as verified by NMR. LDDM also produced a BRD4 binder with an affinity of 40–60 µM, whose NMR‑observed binding matched the model’s prediction. In the SARS‑CoV‑2 Mac1 challenge, LDDM screened only 57 molecules and identified a chemically distinct hit at 46.2 µM; X‑ray analysis confirmed its pose with an accuracy of 1.4–2.3 Å, whereas a public competition of 23 teams had yielded a best result near 18 µM after testing 1739 compounds.
The model failed to give a clear signal for KRAS, and for Pin1 the crystal pose differed from the prediction. Most hits remain below the potency needed for a drug candidate, which the authors view as a pragmatic compromise enabling experimental testing of designed molecules. Lead author Ilya Igashov — an MIPT graduate and EPFL PhD student under Bruno Correia and Oxford professor Michael Bronstein — notes that LDDM continues the lab’s four‑year trajectory from fragment‑based assembly to de‑novo design and synthesizability prediction.
🔗 Read original →
Nature
Equivariant 3D-conditional diffusion model for molecular linker design
Nature Machine Intelligence - Fragment-based molecular design uses chemical motifs and combines them into bio-active compounds. While this approach has grown in capability, molecular linker methods...
Bone Healing Model Shows Why Osteoporosis Drugs Lose Effect Over Time
Reviews in Endocrine and Metabolic Disorders published a review on 17 September 2026 from the University of California, Davis lab. The authors describe bone recovery as a coordinated action of hormones, immune cells, and the local stem‑cell niche, and show that aging disrupts this coordination at two distinct, partially reversible levels.
A precise definition of skeletal stem cells emerged in 2018 when a Stanford team isolated and functionally validated such cells in humans using surface markers; that work has been cited over 600 times. Before this, the field relied on the ill‑defined term “mesenchymal stem cells,” a heterogeneous mix lacking reliable links to outcomes.
One of the 2018 discoverers, Thomas Ambrosi, moved to Davis in 2024 and, with co‑author Kun Chen in 2025, demonstrated that human skeletal stem cells exist in at least four states; the state that activates depends on the cell’s anatomical niche and its specific microenvironment.
Bone itself secretes hormones such as osteocalcin and FGF23 that influence brain, kidney, and metabolism. Fracture healing proceeds through an active hematoma: neutrophils build a temporary matrix within 48 hours, then macrophages pass through four states from inflammatory to reparative. Administering mice the CSF1R blocker pexidartinib from days 3 to 14 after fracture reduces macrophage accumulation, lessens scarring, and accelerates union.
Aging affects the system on two levels. Young blood rejuvenates many tissues—parabiosis of old and young mice extends old‑mouse lifespan by 10%—but does not restore skeletal stem‑cell function; Ambrosi’s earlier work showed these cells lose bone‑forming capacity and are not rescued by young‑blood infusion or hematopoietic transplant. In contrast, the niche defect is reversible: declining tenascin C with age impairs macrophage recruitment to injury, and restoring this protein in mice renews old animals’ bone‑healing ability.
Osteoporosis afflicts one third of women and one fifth of men over 50 according to the International Osteoporosis Foundation, leading to as many as up to 37 million fractures per year. Estrogen deficiency directly harms skeletal stem cells, while glucocorticoids disrupt bone‑vascular coupling via the protein basigin; blocking basigin with an antibody prevents bone loss in mice (demonstrated by
🔗 Read original →
Reviews in Endocrine and Metabolic Disorders published a review on 17 September 2026 from the University of California, Davis lab. The authors describe bone recovery as a coordinated action of hormones, immune cells, and the local stem‑cell niche, and show that aging disrupts this coordination at two distinct, partially reversible levels.
A precise definition of skeletal stem cells emerged in 2018 when a Stanford team isolated and functionally validated such cells in humans using surface markers; that work has been cited over 600 times. Before this, the field relied on the ill‑defined term “mesenchymal stem cells,” a heterogeneous mix lacking reliable links to outcomes.
One of the 2018 discoverers, Thomas Ambrosi, moved to Davis in 2024 and, with co‑author Kun Chen in 2025, demonstrated that human skeletal stem cells exist in at least four states; the state that activates depends on the cell’s anatomical niche and its specific microenvironment.
Bone itself secretes hormones such as osteocalcin and FGF23 that influence brain, kidney, and metabolism. Fracture healing proceeds through an active hematoma: neutrophils build a temporary matrix within 48 hours, then macrophages pass through four states from inflammatory to reparative. Administering mice the CSF1R blocker pexidartinib from days 3 to 14 after fracture reduces macrophage accumulation, lessens scarring, and accelerates union.
Aging affects the system on two levels. Young blood rejuvenates many tissues—parabiosis of old and young mice extends old‑mouse lifespan by 10%—but does not restore skeletal stem‑cell function; Ambrosi’s earlier work showed these cells lose bone‑forming capacity and are not rescued by young‑blood infusion or hematopoietic transplant. In contrast, the niche defect is reversible: declining tenascin C with age impairs macrophage recruitment to injury, and restoring this protein in mice renews old animals’ bone‑healing ability.
Osteoporosis afflicts one third of women and one fifth of men over 50 according to the International Osteoporosis Foundation, leading to as many as up to 37 million fractures per year. Estrogen deficiency directly harms skeletal stem cells, while glucocorticoids disrupt bone‑vascular coupling via the protein basigin; blocking basigin with an antibody prevents bone loss in mice (demonstrated by
🔗 Read original →
PubMed Central (PMC)
An Interview with Cell Therapy Pioneer, Arnold Caplan